New HCV pills drive U.S. drug spending up 13.1%

New treatments for hepatitis C have been found to be effective, but expensive. A new report has found that these new drugs account for a 13.1 percent increase in U.S. prescription drug spending in 2014, according to a Medscape report.

Advertisement
Carrie Pallardy

Spending on hepatitis C treatments, including options from Gilead Sciences and AbbVie, increased 734 percent from 2013 to 2014.

Spending on specialty drugs, including treatments for conditions such as HCV, cancer and multiple sclerosis, accounted for 31 percent of drug spending last year, according to the report.

More articles on gastroenterology:
FDA advisory panel to discuss ‘superbug’ infections
3 MUSE procedures for GERD performed in Italy
Loyola University Health System adds Dr. Lesley Rhee

At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.

Register to Attend Webinar

Building a High-Performance Cardiac PET Program: What Health Systems Should Consider

Thursday, July 30
12:00 PM - 1:00 PM CDT

Presenters: Rupa Sanghani, MD, FACC, FASNC, Rush University Medical CenterBrendon Loiselle, CDL Nuclear Technologies

Advertisement

Next Up in GI & Endoscopy

Advertisement

Comments are closed.